Mixed Connective Tissue Disease & Overlap Syndromes
Medicine · Rheumatology · lean revision notes
Mixed Connective Tissue Disease & Overlap Syndromes
Overlap syndromes are autoimmune disorders in which a patient simultaneously fulfils criteria for more than one classic connective tissue disease (CTD). This note focuses on Mixed Connective Tissue Disease (MCTD), Sjögren syndrome, and inflammatory myopathies (polymyositis/dermatomyositis) — each tightly linked to a signature autoantibody, a recurring NEET PG theme.
Defining the overlap concept
A "pure" CTD (SLE, systemic sclerosis/scleroderma, polymyositis, rheumatoid arthritis) has a recognisable phenotype and autoantibody profile. When features blur across two or more of these, the umbrella term is overlap syndrome. MCTD is a specific, named overlap with its own defining antibody, whereas Undifferentiated CTD (UCTD) describes patients with autoimmune features who do not yet meet criteria for any one disease.
High-yield: MCTD is NOT simply "any overlap." It is a distinct entity defined by high-titre anti-U1 ribonucleoprotein (anti-U1 RNP) antibody combined with overlapping features of SLE, systemic sclerosis, and polymyositis.
| Term | What it means |
|---|---|
| MCTD | Defined overlap with anti-U1 RNP; SLE + SSc + PM features |
| Overlap syndrome | Meets criteria for ≥2 distinct CTDs |
| UCTD | Autoimmune features, no full criteria for any single CTD |
| Sharp syndrome | Historical eponym for MCTD (Gordon Sharp, 1972) |
Mixed Connective Tissue Disease (MCTD)
Etiology and pathophysiology
MCTD is an autoimmune disorder of unknown trigger with a strong genetic association to HLA-DR4. The hallmark is an immune response directed at the U1 small nuclear ribonucleoprotein (U1 snRNP) complex — specifically the 70-kDa polypeptide, A, and C proteins bound to U1 RNA. The antibody is present in high titre (a defining feature; low titres are non-specific and seen in SLE).
Pathologically there is widespread proliferative vasculopathy — intimal proliferation and medial hypertrophy of medium and small vessels (unlike the bland vasculopathy of pure SSc), which underlies the dreaded pulmonary arterial hypertension (PAH), the leading cause of death.
High-yield: The single most important antibody is anti-U1 RNP. Notably, anti-dsDNA and anti-Sm are characteristically ABSENT in MCTD — their presence points toward SLE and predicts worse renal disease.
Clinical features
The disease often evolves over years; early features overlap, and over time it may "differentiate" into a dominant disease (usually SSc or SLE). Classic features:
- Raynaud phenomenon — very early, almost universal (>90%); often the first symptom.
- Swollen "puffy" hands / sausage digits (dactylitis) — a near-signature finding.
- Arthritis/arthralgia — frequently more erosive/deforming than SLE; may resemble RA (RF can be positive).
- Myositis — proximal muscle weakness, raised creatine kinase (PM-like).
- Oesophageal dysmotility — like SSc.
- Pulmonary involvement — interstitial lung disease and PAH.
- Sclerodactyly, but renal disease and severe CNS disease are uncommon (a discriminator from SLE).
High-yield: Triad to remember for MCTD = Raynaud + puffy hands + arthritis, with anti-U1 RNP positive and anti-dsDNA/anti-Sm negative. PAH is the commonest cause of mortality. Severe glomerulonephritis is uncommon.
Diagnosis
There is no single universally adopted criteria set; the Alarcón-Segovia and Kasukawa criteria are most used. A common framework:
Serologic requirement: high-titre anti-U1 RNP → PLUS ≥3 clinical features (oedema of hands, synovitis, myositis, Raynaud, acrosclerosis).
Investigations: ANA is positive in a high-titre speckled pattern (reflecting anti-RNP). Always screen for the complications — echocardiography for PAH, HRCT and PFTs for ILD.
Management
- Raynaud → calcium channel blockers (nifedipine); avoid cold/beta-blockers.
- Arthritis/myositis/serositis → corticosteroids ± methotrexate, azathioprine, mycophenolate.
- PAH (the key prognostic determinant) → endothelin receptor antagonists (bosentan), PDE-5 inhibitors (sildenafil), prostacyclin analogues.
- Generally steroid-responsive, giving a better prognosis than pure SSc — provided PAH is detected early.
Prognosis & evolution. A subset of MCTD patients remain stable for years, while others "differentiate" toward a dominant illness — most commonly systemic sclerosis (worsening sclerodactyly, ILD, oesophageal disease) or SLE. The 10-year survival is around 80%, but is dominated by the development of pulmonary arterial hypertension, which can be insidious — hence annual echocardiography and PFTs (looking for an isolated fall in DLCO) are recommended even in stable patients. The proliferative vasculopathy of MCTD is mechanistically why PAH (rather than parenchymal ILD alone) drives mortality, distinguishing it from the bland vasculopathy of limited SSc.
High-yield: An isolated, disproportionate fall in DLCO on PFTs is an early warning of evolving pulmonary hypertension in MCTD and connective tissue disease generally — test before the patient becomes symptomatic.
Sjögren syndrome
Definition and classification
A chronic autoimmune exocrinopathy with lymphocytic infiltration of exocrine (especially lacrimal and salivary) glands, producing the sicca complex — dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia).
- Primary Sjögren — occurs alone.
- Secondary Sjögren — accompanies another CTD, most often rheumatoid arthritis, also SLE/SSc.
Strongly female-predominant (≈9:1), peak in middle age. HLA associations: HLA-DR3 / HLA-B8 (primary).
Autoantibodies and pathophysiology
CD4+ T-lymphocyte–driven glandular destruction with B-cell hyperreactivity. Antibodies:
| Antibody | Note |
|---|---|
| Anti-Ro / SSA | Most associated; also crosses placenta → neonatal lupus & congenital heart block |
| Anti-La / SSB | More specific for Sjögren; usually with anti-Ro |
| Rheumatoid factor | Frequently positive |
| ANA | Positive, often high titre |
High-yield: Anti-Ro (SSA) and anti-La (SSB) are the markers. Maternal anti-Ro is the classic cause of congenital complete heart block in the fetus — a repeatedly tested fact.
Clinical features
- Ocular: grittiness, foreign-body sensation, dryness → corneal damage (filamentary keratitis).
- Oral: dry mouth, difficulty swallowing dry food, dental caries, oral candidiasis, parotid gland enlargement.
- Extraglandular: arthralgia, Raynaud, interstitial nephritis with distal (type 1) renal tubular acidosis, interstitial lung disease, peripheral neuropathy, palpable purpura/cutaneous vasculitis.
- Most feared complication: a markedly increased risk of B-cell non-Hodgkin lymphoma (MALT type) — classically presenting as persistent/unilateral parotid swelling.
High-yield: Sjögren carries a ~16–44× increased risk of non-Hodgkin (MALT) lymphoma — the single most exam-relevant complication. New persistent parotid enlargement = rule out lymphoma.
Diagnosis and investigation of choice
Stepwise approach:
- Schirmer test — filter paper in lower conjunctival sac for 5 minutes; < 5 mm wetting = abnormal (reduced tear production).
- Rose Bengal / lissamine green staining and tear break-up time — detect ocular surface damage.
- Unstimulated salivary flow and sialography/scintigraphy.
- Autoantibodies — anti-Ro/anti-La.
- Minor (labial) salivary gland biopsy — the investigation of choice / most specific → shows focal lymphocytic sialadenitis; focus score ≥ 1 (≥1 aggregate of ≥50 lymphocytes per 4 mm²) is diagnostic.
High-yield: Minor salivary gland (labial) biopsy showing focal lymphocytic infiltration (focus score ≥1) is the most specific confirmatory test. Schirmer test < 5 mm/5 min quantifies the dry eye.
Management
Largely symptomatic: artificial tears, pilocarpine/cevimeline (muscarinic agonists) for secretions, meticulous dental care, punctal occlusion. Hydroxychloroquine for arthralgia/fatigue; immunosuppression (steroids, rituximab) reserved for severe extraglandular disease/vasculitis.
Mnemonic for the sicca evaluation — "DRY": Decreased tears (Schirmer < 5 mm), Rose Bengal/lissamine staining, Yield on labial biopsy (focal lymphocytic sialadenitis). Combine with anti-Ro/La to satisfy classification criteria (ACR-EULAR 2016 uses a weighted score in which the biopsy focus score ≥1 and anti-Ro positivity each carry 3 points).
Polymyositis (PM) & Dermatomyositis (DM)
Definition and pathophysiology
Idiopathic inflammatory myopathies causing symmetrical proximal muscle weakness. The immunopathology differs:
| Feature | Polymyositis | Dermatomyositis |
|---|---|---|
| Mechanism | Cell-mediated (CD8+ T cells) attacking myofibres expressing MHC-I | Humoral / complement-mediated microangiopathy (CD4+, B cells) |
| Histology | Endomysial infiltrate, scattered fibre necrosis | Perifascicular atrophy, perimysial/perivascular infiltrate |
| Skin | Absent | Characteristic rash present |
| Malignancy link | Lower | Strong (esp. ovary, lung, GI, breast, nasopharynx) |
| Vessel deposits | — | MAC (C5b-9) in capillaries |
Clinical features
- Proximal, symmetrical muscle weakness — difficulty rising from chair, climbing stairs, combing hair; painless weakness is typical (pain is mild). Distal strength preserved until late.
- Dysphagia (pharyngeal/oesophageal striated muscle) — poor prognostic sign.
- Interstitial lung disease — strongly linked to anti-Jo-1 (antisynthetase syndrome).
- DM-specific skin signs (mnemonic worthy):
- Heliotrope rash — violaceous discolouration of the upper eyelids with oedema.
- Gottron papules — scaly violaceous papules over the knuckles (MCP/PIP), elbows, knees.
- Shawl sign / V-sign — erythema over upper back/chest.
- Mechanic's hands — cracked, fissured lateral fingers (antisynthetase).
- Holster sign, periungual telangiectasia, calcinosis cutis (juvenile DM).
High-yield: Heliotrope rash + Gottron papules are pathognomonic of dermatomyositis. In an adult with new DM, screen aggressively for occult malignancy.
Antisynthetase syndrome
The triad linked to anti-Jo-1 (anti-histidyl-tRNA synthetase): Myositis → Interstitial lung disease → Arthritis, plus mechanic's hands, Raynaud, fever.
High-yield: Anti-Jo-1 = antisynthetase syndrome, dominated by interstitial lung disease (a major determinant of prognosis). Other myositis-specific antibodies: anti-Mi-2 (classic DM rash, good prognosis), anti-SRP (severe necrotising, poor response), anti-MDA-5 (amyopathic DM with rapidly progressive ILD), anti-TIF1-γ / anti-NXP-2 (malignancy association).
Diagnosis (Bohan & Peter criteria) and investigation of choice
Classic Bohan and Peter criteria (5):
- Symmetric proximal muscle weakness
- Elevated muscle enzymes (CK most sensitive; also aldolase, AST, LDH)
- EMG — myopathic: short, small, polyphasic motor units; fibrillations; complex repetitive discharges
- Muscle biopsy — inflammation/necrosis (the definitive/gold-standard test)
- Characteristic skin rash (only for DM)
Stepwise diagnostic flow: Proximal weakness → raised CK → EMG (myopathic) → MRI to localise → muscle biopsy to confirm → autoantibody panel → malignancy screen (esp. DM/adult).
High-yield: Muscle biopsy is the gold standard. Perifascicular atrophy = dermatomyositis; endomysial CD8+ infiltrate = polymyositis. CK is the most useful enzyme for diagnosis and monitoring. MRI (STIR) best identifies oedematous muscle for biopsy targeting.
Management
- First-line / drug of choice: high-dose corticosteroids (prednisolone 1 mg/kg/day), tapered on clinical + CK response.
- Steroid-sparing agents: methotrexate or azathioprine (first add-ons); mycophenolate.
- Refractory / ILD: IV immunoglobulin (especially good in DM), rituximab, cyclophosphamide for severe ILD.
- Always: physiotherapy, malignancy surveillance, screen swallowing.
Key differentials
| Mimic | Distinguishing clue |
|---|---|
| SLE | Anti-dsDNA/anti-Sm positive, severe nephritis, low complement |
| Systemic sclerosis | Anti-Scl-70 / anti-centromere, skin tightening, renal crisis |
| Inclusion body myositis | Older male, distal + asymmetric weakness, poor steroid response, rimmed vacuoles |
| Statin myopathy / hypothyroid myopathy | Drug/TSH history, no rash, resolves on withdrawal/replacement |
| Polymyalgia rheumatica | Pain/stiffness (not true weakness), normal CK, high ESR, dramatic low-dose steroid response |
| Eaton-Lambert / myasthenia | Fatigable weakness, NMJ antibodies, normal CK |
Recently asked / exam angle
- "High-titre anti-U1 RNP with puffy hands and Raynaud, dsDNA negative" → MCTD; the commonest cause of death is pulmonary arterial hypertension.
- "Investigation of choice in Sjögren" → minor (labial) salivary gland biopsy showing focal lymphocytic sialadenitis; Schirmer test < 5 mm/5 min.
- "Mother with anti-Ro (SSA), baby with bradycardia" → congenital complete heart block / neonatal lupus.
- "Persistent unilateral parotid swelling in long-standing Sjögren" → suspect MALT/non-Hodgkin lymphoma.
- Image-based: heliotrope rash / Gottron papules → dermatomyositis → next step: malignancy screen; rash over knuckles is Gottron (vs SLE rash spares knuckles).
- "Perifascicular atrophy on biopsy" → dermatomyositis; "endomysial CD8 infiltrate" → polymyositis.
- "Myositis + ILD + mechanic's hands" → antisynthetase (anti-Jo-1) syndrome.
- Antibody matching MCQs: anti-Jo-1 = myositis-ILD; anti-Mi-2 = DM with good prognosis; anti-SRP = necrotising myopathy; anti-MDA-5 = rapidly progressive ILD/amyopathic DM.
Rapid revision
- MCTD = anti-U1 RNP (high titre) + overlap of SLE, SSc, PM; dsDNA & Sm absent.
- MCTD classic triad: Raynaud + puffy/swollen hands + arthritis; PAH = leading cause of death; renal disease uncommon.
- MCTD is generally steroid-responsive; HLA-DR4 association; eponym = Sharp syndrome.
- Sjögren markers: anti-Ro (SSA) and anti-La (SSB); anti-Ro → congenital heart block.
- Sjögren = sicca (dry eyes + dry mouth) from lymphocytic exocrine infiltration; HLA-DR3/B8.
- Schirmer test < 5 mm in 5 min = abnormal tear production.
- Sjögren investigation of choice = minor salivary gland biopsy, focus score ≥1 = focal lymphocytic sialadenitis.
- Sjögren's feared complication = non-Hodgkin (MALT) B-cell lymphoma; also distal RTA type 1.
- PM/DM = symmetric proximal painless weakness; CK is the key enzyme.
- Heliotrope rash + Gottron papules = dermatomyositis; adult DM → hunt for malignancy.
- Biopsy: perifascicular atrophy = DM; endomysial CD8+ = PM; PM is CD8/MHC-I cell-mediated.
- Anti-Jo-1 = antisynthetase syndrome (myositis + ILD + arthritis + mechanic's hands); treatment of choice for inflammatory myopathy = corticosteroids.